HCPCS Level II code J7204 designates an injectable recombinant factor VIII product (EsperaCT), glycopegylated, billed per international unit for treatment of hemophilia A. The code captures provision of a long-acting antihemophilic factor used for prophylaxis and management of bleeding episodes. Nationally, coverage and payment for high-cost biologic factor products carry implications for specialty pharmacy, infusion services, and payer formularies due to supply, dosing variability, and clinical necessity.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of clinical context for factor VIII replacement, typical sites of service for administration, and an overview of payer coverage patterns. The publication summarizes available benchmarks for utilization and reimbursement, highlights policy and coding considerations relevant to billing per international unit, and outlines common billing modifiers and administrative factors affecting claims processing.

This summary is intended to orient billing staff, revenue cycle teams, infusion clinicians, and policy analysts to the purpose of J7204, common operational settings, and the payer landscape that influences access to recombinant factor VIII therapies.